Here is why GSK will easily surge to $100 - $125 range in a couple weeks
First, I own the forums at avianflutalk.com and ebolainfo.org where we track things very closely. I don't actively trade stocks in the market, but I jumped in for this event. There is a current race to develop the vaccine and there are 3 candidates. One of them is J&J and they're about a year out so not even in the race. The other two are Merck and Glaxo, which Glaxo is leading. Merck had a problem with their vax and trials were temporarily suspended due to side effects i.e. severe joint pain. Glaxo, had no side effects.
In addition, the world health organization just announced phase 2 trials in West Africa at the end of this month, and the disbursement of around 27,000 doses by Merck and Glaxo, but again, Merck's has side effects. What this means is that the vaccinations is about to begin with Glaxo leading the way by far. Not only will GSK go to $100+ for winning the great vaccine race, but it's currently trading $20 under Merck and is is severely undervalued.
Pivotal Ebola vaccine trials to start this month or next: WHO
GENEVA (Reuters) - Final-stage trials of experimental Ebola vaccines will begin in January or February in the worst-hit West African countries as scientists and drugmakers race to block the deadly disease, the World Health Organization said on Thursday.
If effective, the shots will be available for deployment a few months later.
Nearly 90 experts from vaccine manufacturers, regulatory agencies and health ministries met at WHO headquarters to review data from initial safety trials and finalise plans for pivotal Phase III clinical trials in Liberia, Sierra Leone and Guinea.
"It is my understanding that no major safety signals have been reported to date," WHO director-general Margaret Chan told the talks in opening remarks obtained by Reuters.
"We all want the momentum and sense of urgency to continue," she said. "Too many health care workers are still getting infected, including nationals and doctors and nurses from foreign medical teams."
The meeting is discussing three different large-scale clinical trial designs using the most advanced vaccines to fight a disease that has killed more than 8,000 people in the past year.
Two vaccines from GlaxoSmithKline and another from a collaboration between NewLink Genetics and Merck started initial clinical testing in the autumn. A third one from Johnson & Johnson and Bavarian Nordic has just reached the first-in-human testing stage. Officials from GSK, Merck and J&J all addressed the closed-door meeting. In addition, officials heard from developers of earlier-stage vaccines, including U.S.-based Novavax and Russia's Influenza Research Institute.
The talks also assessed the funding situation, after the GAVI global vaccines alliance said last month it was committing up to $300 million to buy Ebola shots. [ID:L6N0TV24K]
Sierra Leone, the country worst affected by Ebola, plans to start vaccine trials in the second half of January, Samuel Kargbo of its health ministry told Reuters Television on the sidelines of the Geneva talks.
Ebola continues to spread in the Liberian capital of Monrovia, with cases scattered throughout the city, making it hard to identify distinct chains of transmission, Chan said.
"Many believe that the virus has moved from the cities into extremely remote rural areas, making it difficult to see what is really happening in Liberia," she said.
Keiji Fukuda, WHO Assistant-Director for Health Security, told Reuters: "There are ups and downs. We have to be very cautious. We don't want people to get the idea this is over."
(Additional reporting by Marina Depetris and Ben Hirschler; Editing by Andrew Heavens)
news.yahoo.com
COMMENT: There are many articles over the last few days that state Glaxo's Ebola vaccine will be used at the end of January. Again if anyone researches, Merck's side effects were pretty bad (as described by some news sources), and I'm not entirely sure theirs will even be used. Slam dunk. Phase 11 trials in West Africa means theyre disbursing the vaccine and ramping up production. |
